Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462252 · ClinicalTrials.gov registry record · Phase 2
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
A Phase 2 study, sponsored by BioLineRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02462252: Completed Phase 2 study, sponsored by BioLineRx.
NCT02462252 is a Phase 2 study that has completed, run by BioLineRx. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462252, a Phase 2 study, has completed, sponsored by BioLineRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
An open label single arm study to assess efficacy and safety of BL-8040 on top of standard immunotherapy regimen of hATG, cyclosporine and steroids in patients with Hypoplastic MDS and AA over the course of a six month (180 day) treatment period.
Interventions
- DRUG Methylprednisolone
- DRUG Cyclosporine
- DRUG BL-8040
- DRUG horse anti-thymocyte globulin (hATG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-10 |
| Est. Completion | 2020-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462252
The ClinicalTrials.gov registry entry for NCT02462252 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioLineRx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methylprednisolone is the first listed.
NCT02462252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02462252 about?
NCT02462252 is a clinical study titled "Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome". An open label single arm study to assess efficacy and safety of BL-8040 on top of standard immunotherapy regimen of hATG, cyclosporine and steroids in patients with Hypoplastic MDS and AA over the course of a six month (180 day) treatment period.
What is the current status of trial NCT02462252?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-10. Estimated completion is 2020-11.
What interventions are being tested in trial NCT02462252?
The interventions under investigation include: Methylprednisolone (DRUG), Cyclosporine (DRUG), BL-8040 (DRUG), horse anti-thymocyte globulin (hATG) (DRUG).
Who is sponsoring clinical trial NCT02462252?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.